α1-adrenergic receptor antagonists: Novel therapy for pituitary adenomas

Molecular Endocrinology

Volumn 19, Issue 12, 2005, Pages 3085-3096

  Fernando, Manory A ^a   Heaney, Anthony P ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR; ANNEXIN; CASPASE 3; CORTICOTROPIN; DOXAZOSIN; FLUORESCEIN ISOTHIOCYANATE; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHENOXYBENZAMINE; PROOPIOMELANOCORTIN; RETINOBLASTOMA PROTEIN; TUMOR NECROSIS FACTOR ALPHA; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTINEOPLASTIC AGENT; CASP3 PROTEIN, HUMAN; CASP3 PROTEIN, MOUSE; CASPASE; NF KAPPAB INHIBITOR ALPHA; NF-KAPPAB INHIBITOR ALPHA;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; ENZYME DEGRADATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOPHYSIS ADENOMA; IMMUNOREACTIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; TRANSCRIPTION INITIATION; TUMOR CELL; ACTH SECRETING ADENOMA; ADENOMA; ANIMAL; BLOOD; CANCER TRANSPLANTATION; CELL CULTURE; CELL CYCLE; DRUG ANTAGONISM; GENETICS; METABOLISM; NUDE MOUSE; TRANSACTIVATION;

ANIMALIA; MURINAE;

ACTH-SECRETING PITUITARY ADENOMA; ADENOMA; ADRENERGIC ALPHA-ANTAGONISTS; ADRENOCORTICOTROPIC HORMONE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CASPASES; CELL CYCLE; CELL PROLIFERATION; DOXAZOSIN; HUMANS; I-KAPPA B PROTEINS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NF-KAPPA B; PRO-OPIOMELANOCORTIN; RECEPTORS, ADRENERGIC, ALPHA-1; TRANS-ACTIVATION (GENETICS); TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 28144434596     PISSN: 08888809     EISSN: 08888809     Source Type: Journal    
DOI: 10.1210/me.2004-0471     Document Type: Article

References (37)

1. Heaney AP, Melmed S 2002 Molecular pathogenesis of pituitary tumors. In: Wass JAH, Shalet SM, eds. Oxford textbook of endocrinology. Vol. 2. Oxford, UK: Oxford University Press; 109-120
2. Freda PU, Wardlaw SL 1999 Clinical review 110. Diagnosis and treatment of pituitary tumors. J Clin Endocrinol Metab 84:3859-3866
3. Heaney AP, Melmed S 2004 Molecular targets in pituitary tumors. Nat Rev Cancer 4:285-294
4. Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G 2003 Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 349:2023-2033
5. Sheppard M 2003 Primary medical therapy for acromegaly. Clin Endocrinol (Oxf) 58:387-399
6. Shomali ME, Katznelson L 2002 Medical therapy of gonadotropin-producing and nonfunctioning pituitary adenomas. Pituitary 5:89-98
7. Liu JK, Weiss MH, Couldwell WT 2003 Surgical approaches to pituitary tumors. Neurosurg Clin N Am 14:93-107
8. Hoybye C, Grenback E, Rahn T, Degerblad M, Thoren M, Hulting AL 2001 Adrenocorticotrophic hormone-producing pituitary tumors: 12 to 22-year follow-up after treatment with stereotactic radiosurgery. Neurosurgery 49:284-291
9. Barkan AL 2003 Radiotherapy in acromegaly: the argument against. Clin Endocrinol (Oxf) 58:132-135
10. Woollons A, Hunn M, Rajapakse Y, Toomath R, Hamilton D, Conaglens J, Balakrishnan V 2000 Non functioning pituitary adenomas: indications for postoperative radiotherapy. Clin Endocrinol (Oxf) 53:713-717
11. Boelaert K, Gittoes N 2001 Radiotherapy for non-functioning pituitary adenomas. Eur J Endocrinol 144:569-575
12. 1-Adrenergic receptors: new insight and directions. J Pharmacol Exp Ther 298:403-410
13. 1-Adrenoceptor subtypes on rat afferent arterioles assessed by radioligand binding and RT-PCR. Am J Physiol Renal Physiol 281:F172-F178
14. Kyprianou N, Litvak JP, Borkowski A, Alexander R, Jacobs SC 1998 Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia. J Urol 159:1810-1850
15. Cal C, Uslu R, Gunaydin G, Ozyurt C, Omay S 2000 Doxazosin: a new cytotoxic agent for prostate cancer? BJU Int 85:672-675
16. Kyprianou N, Benning C 2000 Suppression of human prostate cancer cell growth by α1-adrenoceptor antagonist doxazosin and terazosin via induction of apoptosis. Cancer Res 60:4550-4555
17. Li X, Stark GR 2002 NFκB-dependent signaling pathways. Exp Hematol 30:285-296
18. Hellermann GR, Nagy SB, Kong X, Lockey RF, Mohapatra SS 2002 Mechanism of cigarette smoke condensate-induced acute inflammatory response in human bronchial epithelial cells. Respir Res 3:22-29
19. Wass JAH 2003 Radiotherapy in acromegaly: a protagonists viewpoint. Clin Endocrinol (Oxf) 58:128-131
20. Heaney AP, Fernando M, Melmed S 2003 PPAR-γ receptor ligands: novel therapy for pituitary adenomas. J Clin Invest 111:1381-1388
21. Vance ML 2003 Medical treatment of functional pituitary tumors. Neurosurg Clin N Am 14:81-87
22. Nieman LK 2002 Medical therapy of Cushing's disease. Pituitary 5:77-82
23. Ho A, Dowdy SF 2002 Regulation of G(1) cell-cycle progression by oncogenes and tumor suppressor genes. Curr Opin Genet Dev 12:47-52
24. Narita M, Nunez S, Heard E, Narita M, Lin AW, Hearn SA, Spector DL, Hannon GJ, Lowe SW 2003 Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 113:703-716
25. Black EP, Huang E, Dressman H, Rempel R, Laakso N, Asa SL, Ishida S, West M, Nevins JR 2003 Distinct gene expression phenotypes of cells lacking Rb and Rb family members. Cancer Res 63:3716-3723
26. Pei L, Melmed S, Scheithauer B, Kovacs K, Benedict WF, Prager D 1995 Frequent loss of heterozygosity at the retinoblastoma susceptibility gene (RB) locus in aggressive pituitary tumors: evidence for a chromosome 13 tumor suppressor gene other than RB. Cancer Res 55:1613-1616
27. Simpson DJ, Magnay J, Bicknell JE, Barkan AL, McNicol AM, Clayton RN, Farrell WE 1999 Chromosome 13q deletion mapping in pituitary tumors: infrequent loss of the retinoblastoma susceptibility gene (RB1) locus despite loss of RB1 protein product in somatotrophinomas. Cancer Res 59:1562-1566
28. Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA, Weinber RA 1992 Effects of an Rb mutation in the mouse. Nature 359:295-300
29. Hu N, Gutsmann A, Herbert D, Bradley A, Lee W, Lee E 1994 Heterozygous Rb-1/+ mice are predisposed to tumor of the pituitary gland with a nearly complete penetrance. Oncogene 9:1021-1027
30. Ilio K, Park I, Pins M, Kozlowski J, Lee Chung 2001 Apoptotic activity of doxazosin on prostate stroma in vitro is mediated through an autocrine expression of TGF-β1. Prostate 48:131-135
31. Glassman D, Chon J, Borkowski A, Jacobs S, Kyprianou N 2001 Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-β expression in benign prostatic hyperplasia. Prostate 46:45-51
32. Partin JV, Anglin IE, Kyprianou N 2003 Quinazoline-based α1-adrenoceptor antagonists induce prostate cancer cell apoptosis via TGF-β signaling and IκBα induction. Br J Cancer 88:1615-1621
33. 1-AR) antagonists on cell proliferation and apoptosis in the prostate: Therapeutic implications in prostatic disease. Prostate Suppl 9:42-46
34. Kirby R, Jardin A 1997 Doxazosin in the treatment of benign prostatic hyperplasia. A review of the safety profile in older patients. Prostate Cancer Prostatic Dis 1:84-89
35. 1-Adrenoceptor subtypes on rat afferent arterioles assessed by radioligand binding and RT-PCR. Am J Physiol Renal Physiol 281:F172-F178
36. Neef M, Biecker E, Heller J, Schepke M, Nischalke D, Wolff M, Spengler U, Reichen J, Sauerbruch T 2003 Portal hypertension is associated with increased mRNA levels of vasopressor G-protein-coupled receptors in human hepatic arteries. Eur J Clin Invest 33:240-255
37. Heaney AP, Fernando M, Yong W, Melmed S 2002 Functional PPAR-γ receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med 8:1281-1287